204 related articles for article (PubMed ID: 29508246)
1. A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer.
Graham L; Banda K; Torres A; Carver BS; Chen Y; Pisano K; Shelkey G; Curley T; Scher HI; Lotan TL; Hsieh AC; Rathkopf DE
Invest New Drugs; 2018 Jun; 36(3):458-467. PubMed ID: 29508246
[TBL] [Abstract][Full Text] [Related]
2. A Phase I Study of Abiraterone Acetate Combined with BEZ235, a Dual PI3K/mTOR Inhibitor, in Metastatic Castration Resistant Prostate Cancer.
Wei XX; Hsieh AC; Kim W; Friedlander T; Lin AM; Louttit M; Ryan CJ
Oncologist; 2017 May; 22(5):503-e43. PubMed ID: 28314838
[TBL] [Abstract][Full Text] [Related]
3. Phase I/II study evaluating the safety and clinical efficacy of temsirolimus and bevacizumab in patients with chemotherapy refractory metastatic castration-resistant prostate cancer.
Barata PC; Cooney M; Mendiratta P; Gupta R; Dreicer R; Garcia JA
Invest New Drugs; 2019 Apr; 37(2):331-337. PubMed ID: 30402678
[TBL] [Abstract][Full Text] [Related]
4. Preclinical trial of a new dual mTOR inhibitor, MLN0128, using renal cell carcinoma tumorgrafts.
Ingels A; Zhao H; Thong AE; Saar M; Valta MP; Nolley R; Santos J; Peehl DM
Int J Cancer; 2014 May; 134(10):2322-9. PubMed ID: 24243565
[TBL] [Abstract][Full Text] [Related]
5. A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer.
Armstrong AJ; Shen T; Halabi S; Kemeny G; Bitting RL; Kartcheske P; Embree E; Morris K; Winters C; Jaffe T; Fleming M; George DJ
Clin Genitourin Cancer; 2013 Dec; 11(4):397-406. PubMed ID: 23830964
[TBL] [Abstract][Full Text] [Related]
6. A Phase I Trial of IGF-1R Inhibitor Cixutumumab and mTOR Inhibitor Temsirolimus in Metastatic Castration-resistant Prostate Cancer.
McHugh DJ; Chudow J; DeNunzio M; Slovin SF; Danila DC; Morris MJ; Scher HI; Rathkopf DE
Clin Genitourin Cancer; 2020 Jun; 18(3):171-178.e2. PubMed ID: 32057715
[TBL] [Abstract][Full Text] [Related]
7. AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide.
Seitz AK; Thoene S; Bietenbeck A; Nawroth R; Tauber R; Thalgott M; Schmid S; Secci R; Retz M; Gschwend JE; Ruland J; Winter C; Heck MM
Eur Urol; 2017 Nov; 72(5):828-834. PubMed ID: 28818355
[TBL] [Abstract][Full Text] [Related]
8. A phase 2 study of OSI-906 (linsitinib, an insulin-like growth factor receptor-1 inhibitor) in patients with asymptomatic or mildly symptomatic (non-opioid requiring) metastatic castrate resistant prostate cancer (CRPC).
Barata P; Cooney M; Tyler A; Wright J; Dreicer R; Garcia JA
Invest New Drugs; 2018 Jun; 36(3):451-457. PubMed ID: 29476383
[TBL] [Abstract][Full Text] [Related]
9. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
[TBL] [Abstract][Full Text] [Related]
10. Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe.
de Bono JS; Chowdhury S; Feyerabend S; Elliott T; Grande E; Melhem-Bertrandt A; Baron B; Hirmand M; Werbrouck P; Fizazi K
Eur Urol; 2018 Jul; 74(1):37-45. PubMed ID: 28844372
[TBL] [Abstract][Full Text] [Related]
11. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.
Sternberg CN; Castellano D; Daugaard G; Géczi L; Hotte SJ; Mainwaring PN; Saad F; Souza C; Tay MH; Garrido JM; Galli L; Londhe A; De Porre P; Goon B; Lee E; McGowan T; Naini V; Todd MB; Molina A; George DJ;
Lancet Oncol; 2014 Oct; 15(11):1263-8. PubMed ID: 25242048
[TBL] [Abstract][Full Text] [Related]
12. Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer.
Efstathiou E; Titus M; Wen S; Hoang A; Karlou M; Ashe R; Tu SM; Aparicio A; Troncoso P; Mohler J; Logothetis CJ
Eur Urol; 2015 Jan; 67(1):53-60. PubMed ID: 24882673
[TBL] [Abstract][Full Text] [Related]
13. Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
Smith MR; Saad F; Rathkopf DE; Mulders PFA; de Bono JS; Small EJ; Shore ND; Fizazi K; Kheoh T; Li J; De Porre P; Todd MB; Yu MK; Ryan CJ
Eur Urol; 2017 Jul; 72(1):10-13. PubMed ID: 28314611
[TBL] [Abstract][Full Text] [Related]
14. Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications.
Rathkopf DE; Larson SM; Anand A; Morris MJ; Slovin SF; Shaffer DR; Heller G; Carver B; Rosen N; Scher HI
Cancer; 2015 Nov; 121(21):3853-61. PubMed ID: 26178426
[TBL] [Abstract][Full Text] [Related]
15. A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone- and/or Enzalutamide-Refractory Metastatic Castration-Resistant Prostate Cancer.
Wei XX; Siegel AP; Aggarwal R; Lin AM; Friedlander TW; Fong L; Kim W; Louttit M; Chang E; Zhang L; Ryan CJ
Oncologist; 2018 Jun; 23(6):656-e64. PubMed ID: 29487219
[TBL] [Abstract][Full Text] [Related]
16. Androgen Receptor Modulation Optimized for Response-Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7-expressing Metastatic Castration-resistant Prostate Cancer.
Taplin ME; Antonarakis ES; Ferrante KJ; Horgan K; Blumenstein B; Saad F; Luo J; de Bono JS
Eur Urol; 2019 Dec; 76(6):843-851. PubMed ID: 31542304
[TBL] [Abstract][Full Text] [Related]
17. MLN0128, an ATP-competitive mTOR kinase inhibitor with potent in vitro and in vivo antitumor activity, as potential therapy for bone and soft-tissue sarcoma.
Slotkin EK; Patwardhan PP; Vasudeva SD; de Stanchina E; Tap WD; Schwartz GK
Mol Cancer Ther; 2015 Feb; 14(2):395-406. PubMed ID: 25519700
[TBL] [Abstract][Full Text] [Related]
18. Abiraterone acetate after progression with enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: a multi-center retrospective analysis.
Yamada Y; Matsubara N; Tabata KI; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H; Yano A; Kawakami S
BMC Res Notes; 2016 Oct; 9(1):471. PubMed ID: 27756383
[TBL] [Abstract][Full Text] [Related]
19. A phase 2 trial of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer and without prior chemotherapy (JPN-201 study).
Matsubara N; Uemura H; Satoh T; Suzuki H; Nishiyama T; Uemura H; Hashine K; Imanaka K; Ozono S; Akaza H
Jpn J Clin Oncol; 2014 Dec; 44(12):1216-26. PubMed ID: 25320340
[TBL] [Abstract][Full Text] [Related]
20. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial.
Fizazi K; Massard C; Bono P; Jones R; Kataja V; James N; Garcia JA; Protheroe A; Tammela TL; Elliott T; Mattila L; Aspegren J; Vuorela A; Langmuir P; Mustonen M;
Lancet Oncol; 2014 Aug; 15(9):975-85. PubMed ID: 24974051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
